Literature DB >> 19639188

Peroxisome proliferator-activated receptor delta and gastric cancer (Review).

Chung W Wu1, Jun Yu, Joseph J Y Sung.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily which form heterodimers with retinoid X receptors (RXRs) in nucleus and bind to the PPAR response elements (PPREs) of target genes, leading to a wide spectrum of physiological functions. With an improved understanding of its physiological role, PPARdelta and its agonist have been gaining attention in cancer research in recent years. Despite the paucity of research concerning the direct relationship between PPARdelta and gastric cancer, there is substantial evidence that PPARdelta may play a role in the development of gastric cancer. This review focuses on recent literature describing the role of PPARdelta, especially in its association with nuclear factor-kappaB (NF-kappaB), interleukin-1beta (IL-1beta), cyclooxygenase-2 (COX-2) and Wnt-beta-catenin/TCF-4 pathways on gastric tumorigenesis and highlights critical discrepancies that need to be resolved for a more comprehensive understanding of how this receptor modulates gastric tumorigenesis. The potential role of PPARdelta as a therapeutic target in the treatment of gastric cancer deserves further research focus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19639188

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated.

Authors:  Ambra Pozzi; Vlad Popescu; Shilin Yang; Shaojun Mei; Mingjian Shi; Satu M Puolitaival; Richard M Caprioli; Jorge H Capdevila
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

2.  Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers.

Authors:  Ying Yang; Rita V Burke; Christie Y Jeon; Shen-Chih Chang; Po-Yin Chang; Hal Morgenstern; Donald P Tashkin; Jenny Mao; Wendy Cozen; Thomas M Mack; Jianyu Rao; Zuo-Feng Zhang
Journal:  Lung Cancer       Date:  2014-06-27       Impact factor: 5.705

3.  Genetic variants of peroxisome proliferator-activated receptor δ are associated with gastric cancer.

Authors:  Christie Jeon; Shen-Chih Chang; Lina Mu; Jinkou Zhao; Jian-Yu Rao; Qing-Yi Lu; Zuo-Feng Zhang
Journal:  Dig Dis Sci       Date:  2013-08-02       Impact factor: 3.199

Review 4.  Wnt signalling and the control of cellular metabolism.

Authors:  Jaswinder K Sethi; Antonio Vidal-Puig
Journal:  Biochem J       Date:  2010-03-15       Impact factor: 3.857

5.  β-Catenin and peroxisome proliferator-activated receptor-δ coordinate dynamic chromatin loops for the transcription of vascular endothelial growth factor A gene in colon cancer cells.

Authors:  Injoo Hwang; Jeeho Kim; Sunjoo Jeong
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

6.  The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer.

Authors:  Alessandra Fucci; Tommaso Colangelo; Carolina Votino; Massimo Pancione; Lina Sabatino; Vittorio Colantuoni
Journal:  PPAR Res       Date:  2012-09-06       Impact factor: 4.964

7.  Induction of metastatic gastric cancer by peroxisome proliferator-activated receptorδ activation.

Authors:  Claire B Pollock; Olga Rodriguez; Philip L Martin; Chris Albanese; Xin Li; Levy Kopelovich; Robert I Glazer
Journal:  PPAR Res       Date:  2010-12-27       Impact factor: 4.964

8.  MicroRNA‑190b expression predicts a good prognosis and attenuates the malignant progression of pancreatic cancer by targeting MEF2C and TCF4.

Authors:  Yunwei Li; Zhe Wang; Feng Zhao; Juan Zeng; Xianghong Yang
Journal:  Oncol Rep       Date:  2021-11-15       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.